Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline includes Lenzetto, Evamist, Testosterone Topical Solution, and others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
36
Stocks News & Analysis
stocks
Investment decisions in overvalued bank drive strong results
stocks
Overvalued ASX share hurt by normalising conditions
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,109.40 | 52.50 | 0.58% |
| CAC 40 | 7,950.18 | 14.59 | -0.18% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,987.10 | 74.80 | 0.16% |
| FTSE 100 | 9,682.57 | 53.21 | -0.55% |
| HKSE | 26,654.81 | 412.98 | 1.57% |
| NASDAQ | 23,004.54 | 49.46 | -0.21% |
| Nikkei 225 | 50,911.76 | 635.39 | 1.26% |
| NZX 50 Index | 13,617.48 | 18.27 | 0.13% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,835.90 | 44.10 | 0.50% |
| SSE Composite Index | 4,015.78 | 18.22 | 0.46% |